Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Cell Medica has reported that the first patient has been treated in the CMV~ACE/ASPECT trial at University College Hospital London.
Subscribe to our email newsletter
The Phase II randomised clinical trial is designed to demonstrate the efficacy of adoptive cellular therapy for the pre-emptive treatment of cytomegalovirus (CMV) infections in patients who have received a bone marrow transplant from an unrelated donor.
The study will enroll 36 patients across ten UK hospitals.
The patients in treatment arm will receive CMV-specific memory T cells, while patients in the control arm will receive only conventional antiviral treatment.
Cell Medica is sponsoring the study and providing the majority of the cell therapy products for the patients being treated.
The trial is a collaboration between Cell Medica, Leukaemia & Lymphoma Research, the University of Birmingham and NHS Blood and Transplant (NHSBT).
The study is expected to be completed by the end of 2012 with results to be published in 2013.